Journal of Clinical Microbiology, July 2001, p. 2379-2385, Vol. 39, No. 7
Center for Research in Anti-Infectives and
Biotechnology, Department of Medical Microbiology and
Immunology,1 and Department of
Pathology,3 Creighton University School of
Medicine, Omaha, Nebraska 68178; bioMérieux Inc.,
Hazelwood, Missouri 630422; and
bioMérieux, LaBalme-Les-Grottes, France4
Received 27 October 2000/Returned for modification 12 March
2001/Accepted 18 April 2001
A study was designed to assess the impact of the VITEK 2 automated
system and the Advanced Expert System (AES) on the clinical laboratory
of a typical university-based hospital. A total of 259 consecutive,
nonduplicate isolates of Enterobacteriaceae members, Pseudomonas aeruginosa, and Staphylococcus
aureus were collected and tested by the VITEK 2 system for
identification and antimicrobial susceptibility testing, and the
results were analyzed by the AES. The results were also analyzed by a
human expert and compared to the AES analyses. Among the 259 isolates
included in this study, 245 (94.6%) were definitively identified by
VITEK 2, requiring little input from laboratory staff. For 194 (74.9%)
isolates, no inconsistencies between the identification of the strain
and the antimicrobial susceptibility determined by VITEK 2 were
detected by the AES. Thus, no input from laboratory staff was required for these strains. The AES suggested one or more corrections to results
obtained with 65 strains to remove inconsistencies. The human expert
thought that most of these corrections were appropriate and that some
resulted from a failure of the VITEK 2 system to detect certain forms
of resistance. Antimicrobial phenotypes assigned to the strains by the
AES for
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.7.2379-2385.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Potential Impact of the VITEK 2 System and the
Advanced Expert System on the Clinical Laboratory of a
University-Based Hospital
-lactams, aminoglycosides, quinolones, macrolides,
tetracyclines, and glycopeptides were similar to those assigned by the
human expert for 95.7 to 100% of strains. These results indicate that
the VITEK 2 system and AES can provide accurate information in tests
for most of the clinical isolates examined and remove the need for
human analysis of results for many. Certain problems were identified in
the study that should be remediable with further work on the software
supporting the AES.
Journal of Clinical Microbiology, July 2001, p. 2379-2385, Vol. 39, No. 7
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.7.2379-2385.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. |
|---|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|